In terms of liquidity and interest, the mean open interest for Exact Sciences options trades today is 1016.57 with a total ...

The initial results suggest that Exact’s test could be an alternative to others on the market, but the findings come from a ...

As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical data showing its blood-based test can help spot growing tumors as well ...

Analyst Kyle Mikson CFA of Canaccord Genuity maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price ...

Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug Administration in July.

US diagnostic company Exact Sciences has announced its blood-based colorectal cancer (CRC) screening test algorithm showed a sensitivity of 88% for colorectal cancer and 31% for advanced ...

On Monday, BTIG updated its outlook on Exact Sciences Corp (NASDAQ:EXAS), increasing the price target to $82 from the previous $70 while reiterating a Buy rating on the stock. The adjustment ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal ...

Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new campaign out that marks the first Spanish-language promotional push for the brand.

Data presented show sensitivities of 88% for colorectal cancer and 31% for advanced precancerous lesions at 90% specificity Scientific insights reflect Exact Sciences’ commitment to closing the ...

On Monday, Citi reaffirmed its Buy rating and $80.00 stock price target for Exact Sciences (NASDAQ:EXAS), following the release of promising initial data on the company's blood-based colorectal ...